Sharp Therapeutics Corp. (SHRX.V)
2.20
0.00 (0.00%)
CAD |
TSXV |
Feb 10, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 66.17M |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | 0.00% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | -- |
| Price to Book Value | -- |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | -- |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | -- |
Profile
| Sharp Therapeutics Corp. operates as a biology technology company. It focuses on compounds that improve the function of mutated proteins and enhance the activity of the remaining un-mutated protein copy in haploinsufficiency. The company has developed the CoreX biology, AlloChem chemistry and Disco computational technologies to discover small molecules that restore activity in mutated proteins, or that increase activity in the normal copy of the gene in the case where an only single unmutated gene remains. The firm applies these technologies across a portfolio of diseases of high unmet medical need. The company was founded on October 4, 2021 and is headquartered in Pittsburgh, PA. |
| URL | http://www.sharptx.com |
| Investor Relations URL | N/A |
| HQ State/Province | Pennsylvania |
| Sector | |
| Industry | |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| Sharp Therapeutics Corp. operates as a biology technology company. It focuses on compounds that improve the function of mutated proteins and enhance the activity of the remaining un-mutated protein copy in haploinsufficiency. The company has developed the CoreX biology, AlloChem chemistry and Disco computational technologies to discover small molecules that restore activity in mutated proteins, or that increase activity in the normal copy of the gene in the case where an only single unmutated gene remains. The firm applies these technologies across a portfolio of diseases of high unmet medical need. The company was founded on October 4, 2021 and is headquartered in Pittsburgh, PA. |
| URL | http://www.sharptx.com |
| Investor Relations URL | N/A |
| HQ State/Province | Pennsylvania |
| Sector | |
| Industry | |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |